XML 63 R45.htm IDEA: XBRL DOCUMENT
v3.19.1

LICENSED TECHNOLOGY (Details Textual) | 1 Months Ended | 12 Months Ended
--- | --- | ---
Nov. 04, 2019 USD ($) | Nov. 04, 2018 USD ($) | Jan. 23, 2015 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($)
Finite-Lived Intangible Asset, Useful Life |  |  |  | 20 years |  |
Payable Due Licensor Non current |  |  |  | $ 20,000,000 | $ 0 |
Amortization of Intangible Assets |  |  |  | 1,186,000 | 534,000 | $ 677,000
Payable Due Licensor Current |  |  |  | $ 10,000,000 | $ 0 |
Abeona Therapeutics LLC [Member] |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  | 20 years |  |
EB Agreement [Member] |  |  |  |  |  |
Number Of License Agreements Research And Development Arrangements |  |  |  | 2 |  |
Plasma Technologies, LLC [Member] |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  | 11 years |  |
License Costs |  |  | $ 1,000,000 |  |  |
REGENXBIO [Member] | Licensing Agreements [Member] |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life | 8 years |  |  |  |  |
Payable Due Licensor Non current | $ 20,000,000 | $ 20,000,000 |  |  |  |
Guranteed Upfront Payment |  | 20,000,000 |  |  |  |
Payment on Execution of Contracts |  | 10,000,000 |  |  |  |
Annual Fees |  | 100,000,000 |  |  |  |
Milestone Payment |  | $ 60,000,000 |  |  |  |
REGENXBIO [Member] | Licensing Agreements [Member] | Scenario, Forecast [Member] |  |  |  |  |  |
Payable Due Licensor Current | $ 10,000,000 |  |  |  |  |

X
- Definition Represents the total annual fees payable on the contract. + References No definition available. + Details
Name: | abeo_AnnualFees
Namespace Prefix: | abeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of upfront payment to be made. + References No definition available. + Details
Name: | abeo_GuranteedUpfrontPayment
Namespace Prefix: | abeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. + References No definition available. + Details
Name: | abeo_LicensCosts
Namespace Prefix: | abeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount to be paid on future date on the completion of certain milestone on the contract. + References No definition available. + Details
Name: | abeo_MilestonePayment
Namespace Prefix: | abeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Refers to the number of licensing agreements under research and development arrangements. + References No definition available. + Details
Name: | abeo_NumberOfLicenseAgreementsResearchAndDevelopmentArrangements
Namespace Prefix: | abeo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount payable due to licensor. + References No definition available. + Details
Name: | abeo_PayableDueLicensorCurrent
Namespace Prefix: | abeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount less current portion of payable due to licensor. + References No definition available. + Details
Name: | abeo_PayableDueLicensorNonCurrent
Namespace Prefix: | abeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount to be paid on the execution of contracts under the license agreement. + References No definition available. + Details
Name: | abeo_PaymentOnExecutionOfContracts
Namespace Prefix: | abeo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=abeo_AbeonaTherapeuticsLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abeo_LicenseAgreementTerms2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=abeo_PlasmaTechnologiesLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=abeo_REGENXBIOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |